Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Receptos Inc. Stories

2014-03-18 08:27:07

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 18, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2013-04-04 20:20:59

SAN DIEGO, April 4, 2013 /PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Receptos. The number of shares...

2013-03-13 08:33:45

Development License and Option Agreement Represents Blueprint for Innovation between Pharma and Biotech SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV). The asset, designated RPC4046 by Receptos, has completed a first-in-human Phase I study. Under the agreement, Receptos will conduct a Phase 2 clinical...

2013-02-14 08:29:28

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr. Cooper joins the company after serving as Chief Financial Officer of Geron Corporation and Orexigen Therapeutics, Inc. "Graham brings to Receptos tremendous strategic insight and financial experience, including Orexigen's successful initial public offering," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "Graham will play a key...

2013-01-04 08:22:56

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND) Application...

2012-10-22 07:29:33

SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate receptor 1 (S1P1) modulator, RPC1063, has been administered to the first patient in a Phase 2/3 study. RPC01-201, a Phase 2/3 placebo-controlled (Phase 2) and active comparator-controlled (Phase 3) trial, is the first of two planned pivotal studies for RPC1063 in the indication of relapsing multiple sclerosis (RMS). The Phase 2 portion of RPC01-201 is a randomized,...

2012-10-09 07:27:38

SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver two scientific poster presentations about RPC1063 at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting in Lyon, France, from October 10 to 13, 2012. For a quarter of a century, ECTRIMS has served as Europe's and the world's largest professional organization dedicated to the understanding and treatment of multiple sclerosis...

2012-10-01 02:29:53

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present the Featured Presentation at the 10th Annual Discovery on Target Conference at 8:40 a.m. EDT today at the Copley Marriott Hotel in Boston. Mike Hanson, director of structural biology, will speak about the technological advancements in the field that have enabled GPCR structural biology, with an emphasis on the sphingosine 1-phosphate 1 receptor (S1P1) and adenosine a2a receptor...

2012-08-13 06:25:21

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 9:10 a.m. EDT on Wednesday, August 15, 2012, at the Le Parker Meridien Hotel in New York City. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its Phase 2 clinical development programs for multiple sclerosis and inflammatory bowel disease with...

2012-07-12 10:23:12

SAN DIEGO, July 13, 2012 /PRNewswire/ -- Receptos Inc. announced today the co-publication, in conjunction with the Stevens Lab at The Scripps Research Institute®, of key results relating to its expertise in the determination of high resolution G-protein coupled receptor (GPCR) crystal structures to enable rational drug discovery and design, including for allosteric modulators of GPCR receptors. The article, published in today's issue of Science and titled "Structural Basis for...